<DOC>
	<DOCNO>NCT00522015</DOCNO>
	<brief_summary>show 1. patient improve stabilize 12 -24 week treatment rivastigmine memory function 2. use rivastigmine positive effect apathy PSP patient 3. therapy rivastigmine positive benefit speech overall result MMST 4. change motor activity associate change language overall result MMST</brief_summary>
	<brief_title>Efficacy Study Treatment Dementia Progressive Supranuclear Palsy</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>diagnosis PSP willingness participate study inform consent ability speak CNS diseases write informed consent stable state health ability give inform consent , check independent physician alcohol abuse acute psychosis pregnancy lactation know previous drug reaction hypersensitivity rivastigmine carbamate derivative liver failure know sick sinus syndrome excitation disturbance know ulcus ventriculus duodenal ulcer know asthma COPD seizures renal failure</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>PSP</keyword>
	<keyword>dementia</keyword>
	<keyword>neuropsychology</keyword>
	<keyword>treatment</keyword>
</DOC>